Developing practice recommendations for endovascular revascularization for acute ischemic stroke

ABSTRACT
Guidelines have been established for the management of acute ischemic stroke; however, specific recommendations for endovascular revascularization therapy are lacking. Burgeoning investigation of endovascular revascularization therapies for acute ischemic stroke, rapid device development, and a diverse training background of the providers performing the procedures underscore the need for practice recommendations. This review provides a concise summary of the Society of Vascular and Interventional Neurology endovascular acute ischemic stroke roundtable meeting. This document was developed to review current clinical efficacy of pharmacologic and mechanical revascularization therapy, selection criteria, periprocedure management, and endovascular time metrics and to highlight current practice patterns. It therefore provides an outline for the future development of multisociety guidelines and recommendations to improve patient selection, procedural management, and organizational strategies for revascularization therapies in acute ischemic stroke. Neurology® 2012;79 (Suppl 1):S243–S255

GLOSSARY
ACT = activated clotting time; AHA = American Heart Association; AIS = acute ischemic stroke; ASA = American Stroke Association; ASPECTS = Alberta Stroke Program Early CT score; CI = confidence interval; ECASS = European Cooperative Acute Stroke Study; ED = emergency department; EMS = emergency medical services; ERT = endovascular revascularization therapy; FDA = US Food and Drug Administration; IA = intra-arterial; ICH = intracranial hemorrhage; IMS = Interventional Management of Stroke; J-MUSIC = Japan Multicenter Stroke Investigators’ Collaboration; MCA = middle cerebral artery; MELT = MCA-Embolism Local fibrinolytic intervention Trial; MERCI = Mechanical Embolus Removal in Cerebral Ischemia; MR CLEAN = Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; MR RESCUE = MR and Recanalization of Stroke Clots Using Embolectomy; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; NINDS = National Institute of Neurological Disorders and Stroke; OR = odds ratio; PROACT = Proplyse in Acute Cerebral Thromboembolism; rtPA = recombinant tissue plasminogen activator; sICH = symptomatic ICH; SYNTHESIS EXP = Intra-Arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke; THERAPY = Assess the Penumbra System in the Treatment of Acute Stroke; VBO = vertebrobasilar occlusion.

In an effort to improve outcome in patients with acute ischemic stroke (AIS), recent initiatives have outlined the best medical management and developed protocols to facilitate timely identification and administration of the US Food and Drug Administration (FDA)–approved IV recombinant tissue plasminogen activator (rtPA) to eligible patients.1,2 Restoration of blood flow after AIS is associated with improved outcome and reduced mortality.3,4 A meta-analysis including over 2,000 patients in 53 studies confirmed a strong correlation between recanalization and good functional outcome at 3 months, in comparison with nonrecanalization (odds ratio [OR] 4.43; 95% confidence interval [CI] 3.32–5.91).4 Intra-arterial (IA) thrombolysis has not received FDA approval, but randomized trials and several case series have led to endorsements by multiple associations for select patients.5–9 Endovascular revascularization therapy (ERT) currently has a Class Ib recommendation for IA thrombolysis for select patients and a Level IIb recommendation for mechanical thrombus...
SAFETY AND EFFICACY OF ENDOVASCULAR REVASCULARIZATION THERAPY FOR ACUTE ISCHEMIC STROKE

Endovascular treatment options for intracerebral revascularization have evolved considerably over the past decade. Several trials evaluating the various therapies are summarized in Table 1. The Prolyse in Acute Cerebral Thromboembolism (PROACT) and PROACT II studies evaluated the use of IA thrombolysis with prourokinase in middle cerebral artery (MCA) occlusions. The initial phase 2 trial demonstrated higher recanalization rates with prourokinase. The phase 3 trial, PROACT II, demonstrated the effectiveness of IA thrombolysis with prourokinase in patients with an MCA occlusion treated within 6 hours from symptom onset. A minimum requirement NIH Stroke Scale (NIHSS) score of 4, except for isolated aphasia or hemianopia, was required for enrollment. Patients treated with prourokinase had a higher rate of recanalization (66% vs 18%; \( p < 0.001 \)) and were more likely to have a good outcome (modified Rankin Scale [mRS] score of 0–2 at 90 days, 40% vs 25%; \( p = 0.04 \)), despite a higher rate of symptomatic intracranial hemorrhage (sICH) (10% vs 2%; \( p = 0.06 \)). The MCA-Embolic Local fibrinolytic intervention Trial (MELT) was a similarly designed trial comparing urokinase to placebo in patients with MCA occlusions, which was terminated early because of the approval of the IV administration of rtPA in Japan. Although the MELT findings are underpowered, the results are consistent with those of the PROACT trials, suggesting higher recanalization rates (74%) with IA thrombolysis. A meta-analysis of these 3 trials and 2 additional smaller trials combined 395 randomized patients and showed that IA thrombolysis increased the odds of both nondisabled outcome (mRS score 0–1; OR 2.5; 95% CI 1.33–3.14; \( p < 0.001 \)) and nondependent outcome (mRS score 0–2; OR 14; 95% CI 1.31–3.51; \( p < 0.003 \)). A case-control analysis from Japan’s Multicenter Stroke Investigators’ Collaboration (J-MUSIC) compared 91 patients with an acute cardioembolic stroke treated with IA urokinase within 4.5 hours of symptom onset to a matched control group that did not receive IA therapy. The analysis showed that a favorable outcome (mRS score 0–2) was more frequently observed in the urokinase group (50.5% vs 34.1%; \( p = 0.0124 \)), and there was no difference in mortality rate. Although confirmatory trials required for FDA approval of IA therapy have not been performed, these randomized trials and numerous case series support the use of IA thrombolysis in select patients who are ineligible for IV thrombolysis.

Mechanical devices for ERT have evolved as a means of achieving faster rates of recanalization in medium- to large-vessel occlusions. The Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi-MERCI were prospective, single-arm, multicenter trials designed to test the efficacy and safety of a corkscrew thrombectomy device in the treatment of medium- to large-vessel occlusions (anterior and posterior circulation) within 8 hours of symptom onset. A combined analysis of the 2 studies demonstrated a successful recanalization rate (defined as Thrombolysis in Myocardial Infarction 2 or 3 score) of 64.6%, with good clinical outcome (mRS score 0–2) in 32.4%, despite an sICH rate of 7.8% in the first study and 9.8% in the second. The Penumbra Pivotal Stroke Trial provided registry data on a novel aspiration-thrombectomy device, the Penumbra system, used within 8 hours for large-artery cerebrovascular occlusion. A quarter of the patients achieved an mRS score of less than or equal to 2 at 90 days. Different techniques for measuring recanalization preclude a direct comparison between the rates achieved with MERCI and Penumbra, but both exceed the natural history rate. Randomized trials are ongoing, such as the Local Versus Systemic Thrombolysis for Acute Ischemic...
### Table 1: Data from selected trials of endovascular revascularization therapy for acute ischemic stroke

<table>
<thead>
<tr>
<th>Year</th>
<th>Intervention</th>
<th>Enrollment time, h</th>
<th>Design</th>
<th>No. of patients</th>
<th>Recanalization rate, % of treatment/control</th>
<th>Occlusion site</th>
<th>Mean NIHSS, treatment/control</th>
<th>SICH, % of treatment/control</th>
<th>mRS 0–2 at 90 days, % of treatment/control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>ProUK + IV heparin vs IV placebo (IA saline infusion)</td>
<td>&lt;6</td>
<td>RCT, Phase II</td>
<td>40</td>
<td>58/14</td>
<td>MCA</td>
<td>17/19</td>
<td>15/7</td>
<td>30/21</td>
</tr>
<tr>
<td>1999</td>
<td>ProUK + IV heparin vs IV placebo followed by IA tPA</td>
<td>&lt;6</td>
<td>RCT, Phase II</td>
<td>180</td>
<td>66/18</td>
<td>MCA</td>
<td>17/17</td>
<td>10.9/2</td>
<td>47/67</td>
</tr>
<tr>
<td>1999</td>
<td>IV tPA or IV placebo followed by IA tPA</td>
<td>&lt;3</td>
<td>RCT, Phase II</td>
<td>35</td>
<td>55/10</td>
<td>CCA, ICA, MCA, BA</td>
<td>16/11</td>
<td>11.8/5.6</td>
<td>43</td>
</tr>
<tr>
<td>2004</td>
<td>IV + IA tPA vs IV heparin</td>
<td>&lt;3</td>
<td>RCT, Phase I</td>
<td>81</td>
<td>56</td>
<td>ICA, MCA, VA, BA, SCA, PCA, ACA, AICA, PICA</td>
<td>6</td>
<td>9.9</td>
<td>46</td>
</tr>
<tr>
<td>2007</td>
<td>IV + IA tPA + IV heparin with or without Ekoos</td>
<td>&lt;8</td>
<td>Single arm, safety and feasibility</td>
<td>19</td>
<td>46</td>
<td>ICA, MCA, VA, BA, SCA, PCA, ACA, AICA, PICA</td>
<td>9/2</td>
<td>9.8</td>
<td>28</td>
</tr>
<tr>
<td>2007</td>
<td>MERCI X6 Retriever + IV heparin</td>
<td>&lt;6</td>
<td>Single arm, Prospective</td>
<td>151</td>
<td>46</td>
<td>ICA, MCA, VA, BA</td>
<td>9.9</td>
<td>7.8</td>
<td>49</td>
</tr>
<tr>
<td>2008</td>
<td>UK vs control</td>
<td>&lt;8</td>
<td>RCT</td>
<td>114</td>
<td>46</td>
<td>ICA, MCA, VA, BA</td>
<td>19/14</td>
<td>9.8</td>
<td>18</td>
</tr>
<tr>
<td>2009</td>
<td>L5 Retriever + IV heparin</td>
<td>&lt;8</td>
<td>Single arm, Prospective</td>
<td>164</td>
<td>74</td>
<td>ICA, MCA, VA, BA</td>
<td>14/14</td>
<td>11.2</td>
<td>36</td>
</tr>
<tr>
<td>2010</td>
<td>Penumbra aspiration system + IV heparin</td>
<td>&lt;8</td>
<td>Single arm, safety and feasibility</td>
<td>125</td>
<td>82</td>
<td>ICA, MCA, VA, BA</td>
<td>19</td>
<td>19</td>
<td>25</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACA = anterior cerebral artery; adj tx = adjunctive therapy; AICA = anterior inferior cerebellar artery; BA = basilar artery; CCA = common carotid artery; EMS = Emergency Management of Stroke in Acute Ischemic Stroke; PROACT = Prolyse in Acute Cerebral Thromboembolism trial; RCT = randomized controlled trial; SCA = superior cerebellar artery; SICH = symptomatic intracranial hemorrhage; TICI = thrombolysis in cerebral infarction; TIMI = thrombolysis in myocardial infarction; tPA = tissue plasminogen activator; UK = urokinase; VA = intracranial vertebral artery.

**Note:** Additional details and references are provided in the text for each intervention and study.
window to 4.5 hours in a subgroup of patients, on the basis of results of the European Cooperative Acute Stroke Study III (ECASS III).25,27 Patients presenting after 4.5 hours are not eligible for systemic thrombolysis; however, data exist, as cited previously, for the consideration of IA fibrinolytic administration up to 6 hours from symptom onset in patients with a large- to medium-vessel occlusion.6,12,28 For patients in whom endovascular therapy can be initiated within 8 hours from symptom onset, 2 mechanical revascularization device families have demonstrated safe and feasible rates of recanalization in single-arm, prospective trials.10,11,29 The optimal device for mechanical revascularization has not been identified, and the rapid growth of device technology will likely continue to challenge rigorous clinical evaluation.

Vertebrobasilar artery occlusion (VBO) has an invariably poor outcome if recanalization is not achieved early. The recent literature shows that mortality with acute VBO treated with nonthrombolytic drugs is 80% to 90%, although lower rates of 42% to 60% can be achieved with IA therapy.28,30,31 Success of recanalization and neurologic status before treatment are independent predictors of a favorable outcome after IA therapy.28,30,31 Multiple studies failed to establish a time window that would definitively exclude patients from IA therapy.28 One study found a significantly better clinical outcome in patients with acute VBO treated within 6 hours after symptom onset than in patients treated after 6 hours (favorable outcome of 36% vs 7%; mortality of 52% vs 70%; p = 0.005).28 Other studies demonstrated trends toward better outcome, with shorter duration of symptoms, and no significant association between time to treatment and clinical outcome.30,31 When patients are in a coma or have had prolonged symptoms, additional imaging such as MRI with diffusion and perfusion or CT perfusion might help in identifying those who are likely to benefit from intervention. However, the current application of CT perfusion results to the posterior circulation may be limited.

The trials that shape the current decision patterns have been largely based on time from symptom onset. Data are lacking on the efficacy of ERT beyond 12 hours from symptom onset in patients with posterior circulation occlusion and beyond 8 hours in anterior circulation occlusion.10,11,29,31,32 Given the poor natural history of VBO, revascularization has been considered beyond 12 hours from symptom onset. Enthusiasm continues for a perfusion imaging–based decision algorithm, although rigorous data to support this approach are lacking.33 Further study of perfusion imaging may assist with selection of pa-
Relative contraindications for adjunctive ERT following IV rtPA

- Known subacute bacterial endocarditis with or without mycotic aneurysm and stroke
- Persistent or worsening neurological deficits following IV rtPA administration

Exclusion criteria for ERT

- Arterial stenosis precluding safe access
- Uncontrolled hypertension, defined as systolic blood pressure > 185 mm Hg or diastolic blood pressure > 110 mm Hg that cannot be reasonably treated with antihypertensive medication
- Platelet count < 30,000
- Use of warfarin anticoagulation with INR > 3.0
- Known bleeding diathesis
- Deficits attributable to glucose < 50 mg/dL
- Seizure at onset, if residual deficits are due to a postictal state rather than ischemia

Imaging findings

- Significant mass effect with midline shift
- Intracranial hemorrhage (ICH, SAH, subdural or epidural hematoma)
- Subacute infarct on head CT/MRI that occupies > 1/3 of the MCA territory or > 100 cc of brain tissue
- CNS lesion with high likelihood of hemorrhage should be excluded from IA pharmacologic thrombolysis (brain tumor, abscess, vascular malformation, aneurysm, contusion)
- May consider IA thrombolysis in patients with small unruptured aneurysms or benign tumors with low vascularity

Relative contraindications for ERT therapy

- Intracranial or spinal surgery, head trauma, or stroke in separate vascular territory within 3 months
- History of ICH
- Terminal illness with short life expectancy or severe comorbid illness
- Pregnancy
- Risk vs benefit of clinical symptoms and ability to shield patient must be considered

Known subacute bacterial endocarditis with or without mycotic aneurysm and stroke

- Special consideration may be needed for patients on dabigatran

Relative contraindications for adjunctive ERT following IV rtPA

- Glucose > 400 mg/dL, based on increased ICH risk
- Ongoing hemodialysis or peritoneal dialysis, due to possibly increased ICH risk

Abbreviations: CTP = CT perfusion; DWI MRI = diffusion-weighted MRI; ERT = endovascular revascularization therapy; IA = intra-arterial; ICH = intracerebral hemorrhage; INR = international normalized ratio; MCA = middle cerebral artery; NIHSS = NIH Stroke Scale; rtPA = recombinant tissue plasminogen activator; SAH = subarachnoid hemorrhage.

Future studies may show that for patients who receive IV rtPA and have a clinical presentation suggestive of a large-vessel occlusion, early consideration of ERT may be important. The limited efficacy of IV rtPA in large vessel occlusions is demonstrated by recanalization rates as low as 30% in the proximal MCA and 6% in the terminal internal carotid artery (ICA). Urgent noninvasive vascular imaging can identify patients with a large-vessel occlusion. The interval from a decision to pursue IA intervention to reaching the clot can be long, with time required to obtain consent, transport and prepare the patient, and negotiate tortuous anatomy. Accordingly, an efficient strategy may be to activate the neurointerventional team when a large-vessel occlusion is suspected, without delay in IV rtPA initiation. If dramatic clinical improvement occurs, patients can be rerouted to repeat noninvasive vessel assessment. One retrospective study has shown that in those patients with a contraindication to IV rtPA or whose IV therapy fails, the use of ERT within the first 3 hours after stroke symptom onset has a low sICH rate, of 5.3%.

Patients with fluctuating deficits or continued mild deficits (NIHSS score ≤ 4) following rapid improvement from presentation carry a risk of harboring a large-vessel occlusion with tenuous collateral supply. Failure of collateral supply could lead to acute deterioration; therefore, emergent noninvasive angiography to identify vessel occlusions amenable to ERT may be considered. To date, no randomized clinical trial has compared the natural history of medical treatment alone to early recanalization with ERT in this subset of patients.

For patients in whom ERT is considered, inclusion and exclusion criteria will be needed. Based on the existing clinical trials and guidelines, a framework for the future development of criteria can be outlined (Table 2).

**SELECTION OF ENDOVASCULAR REVASCU-ULARIZATION THERAPY TECHNIQUE** The heterogeneity of AIS characteristics, including thrombus composition, occlusion location, thrombus volume burden, and collateral perfusion, may demand tai-
Intra-arterial thrombolytic dosing and methods from selected trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>PROACT©</th>
<th>PROACT IIø</th>
<th>MELT+</th>
<th>IMS I©</th>
<th>IMS II©</th>
<th>IMS III©</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agent</td>
<td>ProUK</td>
<td>ProUK</td>
<td>UK</td>
<td>rtPA</td>
<td>rtPA</td>
<td>rtPA</td>
</tr>
<tr>
<td>Max dose</td>
<td>Two-tier dose 6 mg and 12 mg</td>
<td>9 mg</td>
<td>600,000 IU</td>
<td>IV rtPA 0.6 mg/kg, 60 mg max, IA rtPA 22 mg</td>
<td>IV rtPA 0.6 mg/kg, 60 mg max, IA rtPA 22 mg</td>
<td>IV rtPA – 0.6 mg/kg, 60 mg max, possibly IA rtPA 22 mg</td>
</tr>
<tr>
<td>Median dose, mg</td>
<td>6 and 12</td>
<td>9</td>
<td>—</td>
<td>—</td>
<td>12</td>
<td>—</td>
</tr>
<tr>
<td>Infusion duration, h</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Infusion location</td>
<td>At proximal one-third of thrombus</td>
<td>Distal to thrombus</td>
<td>2 mg distal to thrombus, then 2 mg into thrombus, then infusion</td>
<td>At site of thrombus, with or without Ekos ultrasound catheter</td>
<td>1 mg distal and 1 mg proximal, then 20 mg over maximum of 2 h</td>
<td></td>
</tr>
<tr>
<td>Mechanical disruption</td>
<td>Prohibited</td>
<td>Prohibited</td>
<td>Only with guidewire or microcatheter</td>
<td>Only with guidewire or microcatheter</td>
<td>Merci device, Ekos, or penumbra device with IA rtPA infusion or microcatheter/IA rtPA infusion</td>
<td></td>
</tr>
<tr>
<td>Intraprocedural systemic thrombo-prophylaxis</td>
<td>Heparin 2,000 IU bolus and 500 IU/h infusion for 4 h</td>
<td>Heparin 2,000 IU bolus and 500 IU/h infusion for 4 h</td>
<td>Heparin 5,000 IU bolus</td>
<td>Heparin 2,000 IU bolus and 450 IU/h infusion</td>
<td>Heparin 2,000 IU bolus and 450 IU/h infusion until the end of the procedure</td>
<td></td>
</tr>
<tr>
<td>Adjunctive antithrombotic agents</td>
<td>Prohibited in first 24 h</td>
<td>Prohibited in first 24 h</td>
<td>Prohibited in first 24 h</td>
<td>Prohibited in first 24 h</td>
<td>Prohibited in first 24 h</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: IA – intra-arterial; IMS – Interventional Management of Stroke trial; IU – international units; MELT – Middle cerebral artery Embolism Local Fibrinolytic intervention Trial; PROACT – Prolyse in Acute Cerebral Thromboembolism trial; rtPA – IV recombinant tissue plasminogen activator; UK – urokinase.

Bridged interventions. For example, greater efficacy and safety may be demonstrated in distal vessel revascularization by use of IA fibrinolytic therapy, vs a mechanical device that may be more difficult to deliver. Alternatively, in large proximal vessel occlusions, greater benefit may be achieved with mechanical thrombectomy. Furthermore, carotid occlusion at the origin of the ICA may be better treated with balloon angioplasty and stent implantation.

Pharmacologic thrombolysis. Local IA thrombolysis efficacy was demonstrated in PROACT II.© This led to an AHA Class I, level of evidence B recommendation that IA thrombolysis is an option for the treatment of selected patients who have AIS under 6 hours duration due to occlusions of the MCA and who are not otherwise candidates for IV rtPA.© Although variability in study designs prohibits direct comparison of the data, theoretically there may be a higher risk of intracerebral hemorrhage (ICH) with chemical IA thrombolysis than with mechanical revascularization. However, increased ICH was not substantiated in a multicenter study.⁶⁹

Microcatheter position during thrombolytic infusion may also theoretically affect recanalization rates. The microcatheter position varies among the studies; in some instances it is placed distal to the thrombus, within the thrombus, or proximal to the thrombus. Some operators will use multiple locations to infuse rtPA throughout the thrombus. The maximum safe dose for IA rtPA is not known; however, if we extrapolate from large clinical trial experience, then a maximum dose of 22 mg, as in the IMS trials, may be a reasonable initial limit.³¹⁴⁰

Bridging therapies. Bridging therapy trials evaluating the combined approach have shown better recanalization rates for medium- to large-vessel occlusions. However, they have shown only trends toward better outcomes in comparison with the IV rtPA–treated subjects in the National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study or a database registry.⁶⁰⁴¹ Potential benefit of bridging therapy increases when the target population is limited to IV rtPA nonresponders (40% IV-IA patients reached functional independence at 3 months, vs 14.9% of recipients of only IV rtPA, among the non-responders [p = 0.012]). This benefit came at the cost of a higher morbidity associated with the bridging therapy (OR 2.14; 95% CI 0.58 –7.83 for sICH).⁴² The early Emergency Management of Stroke Bridging Trial/IMS trials used a protocol of 0.6 mg/kg IV rtPA with up to an additional maximum of 22 mg IA rtPA, which in most patients allowed for the total dose to remain below the NINDS maximum amount of 90 mg (table 3). However, newer bridging studies and the amended IMS III are using full-dose IV rtPA in the combined IV-IA treatment arm.²⁰²¹

Mechanical revascularization. Mechanical techniques for ERT, including thrombectomy, clot retrieval, and thromboaspiration, have shown comparable or slightly higher recanalization rates than IA thrombol-

![Image](https://example.com/image.png)
Table 4  Treatment times in selected studies, in minutes

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of subjects</td>
<td>40</td>
<td>121</td>
<td>62</td>
<td>500</td>
<td>35</td>
<td>56</td>
<td>50</td>
<td>125</td>
<td>305</td>
<td>96</td>
<td>13</td>
<td>50</td>
<td>13</td>
<td>54</td>
<td>57</td>
<td>44</td>
</tr>
<tr>
<td>Treatment</td>
<td>IA proUK or placebo</td>
<td>IA proUK</td>
<td>IV-IA rtPA</td>
<td>IV or IV-A IAT</td>
<td>IA UK</td>
<td>IV-IA or IV-IAT rtPA</td>
<td>IAT or IV rPA</td>
<td>IAT</td>
<td>IV-IA or IA rtPA</td>
<td>IA UK</td>
<td>IV-RS or RS alone</td>
<td>IA UK</td>
<td>IAT UK</td>
<td>IA UK</td>
<td>IV/IA rtPA</td>
<td></td>
</tr>
<tr>
<td>Time-to-door</td>
<td>Onset</td>
<td>105</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time-to-CT/MRI scan: mean (median)</td>
<td>Onset</td>
<td>162 (145)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging-to-GP</td>
<td></td>
<td>161 (135)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT scan-to-microcatheter</td>
<td></td>
<td>81 (65)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time-to-ERT initiation or angiography or GP</td>
<td>SO (330)</td>
<td>SO (319)</td>
<td>SO (217)</td>
<td>SO (123)</td>
<td>SO (125)</td>
<td>SO (b138)</td>
<td>SO (b180)</td>
<td>SO (132)</td>
<td>SO (258)</td>
<td>SO (151)</td>
<td>SO (261)</td>
<td>SO (324)</td>
<td>SO (330)</td>
<td>SO (321)</td>
<td>Door (130)</td>
<td></td>
</tr>
<tr>
<td>GP to max TIMI/TICI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SO to max TIMI/TICI</td>
<td>a(378)</td>
<td>b(342)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT scan-to-max TIMI/TICI</td>
<td></td>
<td>377 (327)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: EMS = Emergency Management of Stroke; ERT = endovascular revascularization treatment; GP = groin puncture; IA = intra-arterial; IAT = intra-arterial therapy (includes thrombolysis and mechanical techniques); IMS = Interventional Management of Stroke trial; MELT = Middle cerebral artery Embolism Local Fibrinolytic Intervention Trial; MERCI = Mechanical Embolus Removal in Cerebral Ischemia; PROACT = Prolyse in Acute Cerebral Thromboembolism trial; PST = Pivotal Stroke Trial; RECANALISE = Recanalisation using Combined intravenous Alteplase and Neurointerventional Algorithm for acute Ischemic Stroke; RS = retrievable stent; rtPA = recombinant tissue plasminogen activator; SO = symptom onset; TICI = thrombolysis in cerebral infarction; TIMI = thrombolysis in myocardial infarction; UK = urokinase.

Target time intervals and triage and transfer strategies

### Multimodal revascularization

Given the heterogeneity of vessel occlusion pathology in AIS, multiple techniques may afford the highest success for revascularization. Small series suggest that multimodal therapies including IA thrombolysis and stent implantation lead to higher recanalization rates. Future studies may find mechanical thrombectomy, IA thrombolysis, and stent implantation, or other modalities more effective for specific subsets of patients who are considered for ERT after full-dose rtPA. Mechanical thrombectomy might be favorable in patients who are considered for ERT after full-dose rtPA, even with reduced or no hemorrhagic complications. The improved recanalization rates of mechanical revascularization might be accompanied by less hemorrhage with the use of retrievable stents. The increased use of IA thrombolytic therapy and stent implantation may be offset by a higher incidence of mechanical thrombectomy device failure, deliverability to distal locations, and the limited availability of IA thrombolysis in clinical practice. Multimodal revascularization is a promising avenue for revascularization in AIS. Further studies are needed to determine the optimal sequence and combination of mechanical and thrombolytic strategies to maximize recanalization rates.
### Table 5 Benchmark times for revascularization therapies and possible intervals for ERT

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Door-to-balloon time 90 min</td>
<td>Door to needle time 60 min</td>
<td>Door to ED 10 min</td>
<td>Needle-to-groin puncture time 60 min</td>
<td>Transfer from outside hospital-initiated, angiography suite activated, team activated</td>
</tr>
<tr>
<td>STEMI confirmed, cardiologist notified 10 min</td>
<td>Door to ED 10 min</td>
<td>In parallel with IV rtPA pathway (1.0 min)</td>
<td>ERT team is notified as soon as large to medium vessel occlusion is suspected (i.e., NIHSS, hyperdense MCA on CT) in eligible patients</td>
<td>Prior to arrival</td>
</tr>
<tr>
<td>ED stabilizes patient, activates cath lab 30 min</td>
<td>Stroke team activation 15 min</td>
<td>Stroke and ERT teams activation In parallel with IV rtPA pathway (1.5 min)</td>
<td>10 min after the eligibility CT scan and before IV bolus</td>
<td>Receiving hospital arrival: Rapid history and exam, review of referring hospital films</td>
</tr>
<tr>
<td>Cath lab and interventionalist ready 60 min</td>
<td>CT scan initiated 25 min</td>
<td>CT scan initiated In parallel with IV rtPA pathway (25 min)</td>
<td>25 min after the eligibility CT scan and after IV bolus initiation</td>
<td>Ancillary brain imaging (i.e., CT perfusion)</td>
</tr>
<tr>
<td>Final check and written consent 70 min</td>
<td>CT scan interpreted, eligibility assessed 45 min</td>
<td>CT scan interpreted, eligibility assessed In parallel with IV rtPA pathway (45 min)</td>
<td>Repeat NIHSS, obtain written consent, repeat CT if clinical worsening</td>
<td>Final check, written consent, patient prepared</td>
</tr>
<tr>
<td>Catherization and PCI-balloon inflation 90 min</td>
<td>IV rtPA infusion 60 min</td>
<td>Groin puncture 90 min</td>
<td>Groin puncture</td>
<td>Groin puncture</td>
</tr>
</tbody>
</table>

Abbreviations: AHA = American Heart Association; AIS = acute ischemic stroke; angio = angiogram; ASA = American Stroke Association; ED = emergency department; ERT = endovascular revascularization therapy; IA = intra-arterial; MCA = middle cerebral artery; NIHSS = NIH Stroke Scale; PCI = percutaneous coronary intervention; rtPA = recombinant tissue plasminogen activator; STEMI = ST segment elevation myocardial infarction.

* From time of arrival to accepting hospital door.

b Time will need to be adjusted to allow for additional imaging if clinical examination worsens or symptoms suggest hemorrhagic transformation.
evaluation and brain imaging before proceeding to the angiography laboratory.

Achieving a 90-minute door-to-puncture time would likely require the neurointerventionalists to play an integral part in the stroke team, because the decisions on treatment strategy may evolve as the patient proceeds through the AIS protocol and IV rtPA evaluation pathway. The ERT protocol should integrate into the IV rtPA pathway. For interhospital transfers, the completed imaging and laboratory studies as well as additional lead time may reduce the target time interval to 60 minutes for door-to-puncture. However, significant delay in hospital transfer may warrant repeat neuroimaging when the patient arrives at the recipient institution. Benchmark times will need to be established for IV nonresponders, with special consideration for additional delay when clinical deterioration following IV rtPA requires a repeat brain imaging prior to ERT.

**Triage and transfer strategies.** The considerable decline in efficacy of revascularization therapies at around 6 to 8 hours from symptom onset demands well-organized triage and transfer strategies.46 Emergency department reorganization has been an area of focus to improve early identification of stroke patients. Tracking door-to-thrombolysis times, positioning a CT/MRI scanner within the department, and having emergency medical services (EMS) send a prehospital notification are steps that have improved thrombolysis access.58 However, given the limited availability of Comprehensive Stroke Center infrastructure, few centers in a given geographic region will have capabilities for providing comprehensive stroke care and 24/7 ERT. This will lead to a high proportion of patients eligible for ERT arriving by interhospital transfer. Transfer delay has been shown to be a major factor limiting the use of ERT in stroke patients, accounting for an estimated odds of treatment decrease by 2.5% for every minute of transfer time.59 To avoid transfer delay, regional protocols for triage of AIS patients by EMS personnel to designated stroke centers has become a focus of prehospital stroke triage policy.60

Alternative strategies include initiation of IV thrombolysis in a referring hospital prior to transfer “drip-and-ship,” followed by further management at the accepting hospital, which may include ERT. A described model of “drip, ship, and retrieve” used full-dose IV rtPA (0.9 mg/kg) followed by ERT with mechanical thrombectomy and thrombo-aspiration, suggesting feasibility in basilar artery occlusion.61 Different models may evolve where the patient receives ERT in an outside hospital and is transferred for further care at a comprehensive stroke center where neurosurgery, neurocritical care, and vascular neurology expertise are available, known as “retrieve-and-ship.” Pay-for-performance measures similar to those for acute myocardial infarction could help facilitate transfer of appropriate patients from primary to comprehensive stroke centers (the hub-and-spoke model).

**GENERAL PREPROCEDURAL AND INTRAPROCEDURAL MANAGEMENT**

**Anesthesia and monitoring.** The type of anesthesia for ERT has been a topic of controversy, with recent reports suggesting worse outcome with use of general endotracheal anesthesia, possibly due to treatment delays and complications from intubation.62,63 Alternatively, conscious sedation may pose a different set of risks related to patient cooperation, especially in those with severe aphasia or neglect, which may negatively influence time to revascularization and procedural success. Furthermore, ancillary monitoring requiring invasive arterial access for blood pressure monitoring and central IV access may also be of limited value and add delay to initiation of therapy. Further study is needed to evaluate sedation methods for ERT. Sedation methods may currently vary among centers.

**Thromboprophylaxis with systemic anticoagulation.** Arterial catheterization carries a risk of thromboembolism, often requiring systemic anticoagulation. Randomized clinical trials of ERT report variable protocols for thromboprophylaxis, including bolus IV heparin infusion of 2,000 to 5,000 units at procedure onset, followed by continuous infusions of approximately 500 units of IV heparin per hour for the procedure duration.6,21 Alternatively, activated clotting time (ACT) values can be obtained with heparin boluses to maintain an ACT at a therapeutic goal. Limited data exist on the safety of heparin anticoagulation during ERT procedures. A subgroup analysis of the MERCI trial showed no association with hemorrhage or 90-day mortality and heparin use.64 A reasonable ACT range may be 250 to 300 seconds during ERT.

**Renal prophylaxis.** Patients with AIS may also have chronic renal impairment, which may worsen with contrast administered during angiography. Interventions designed to prevent contrast-induced nephropathy have not been rigorously studied. Reasonable prophylaxis strategies include hydration with isotonic saline. Recent data have not provided strong support for the administration of N-acetylcysteine.65 The use of sodium bicarbonate infusion may be reasonable for patients with renal insufficiency, but it can be limited by the large volume and time to acquire the solution from the pharmacy. Periprocedural renal prophylaxis for...
ERT in select AIS patients is an important area in need of further investigation.

**POSTPROCEDURAL MANAGEMENT** Imaging. Patients may benefit from postprocedural imaging, including noncontrast head CT or susceptibility-weighted MRI within 16 to 32 hours from ERT. Given the associated risk of hemorrhagic complications with revascularization therapy, urgent head CT or MRI may be needed for clinical deterioration in the postprocedure period. Intraprocedure imaging is also possible in many angiography suites and can offer rapid diagnostic information.

**Neuromonitoring.** Intensive care unit monitoring with staff trained in neurologic patient care may be important for postprocedure neuromonitoring, including frequent neurologic examination assessments by nursing staff experienced and trained in neurovascular diseases. Intensive monitoring would also include surveillance for groin-access complications and the appropriate management. Stroke severity and outcome scales may be important in performance monitoring.

**Blood pressure management.** Patients in whom revascularization was successful may be at risk of reperfusion hemorrhage, thereby warranting aggressive blood pressure control. Common practice has followed a protocol similar to that for post IV rtPA administration with vigilant blood pressure monitoring for at least the first 24 hours. Blood pressure is measured every 15 minutes for 2 hours, then every 30 minutes for 6 hours, and every hour for 18 hours. Goal blood pressure is targeted to remain below 180/105 mm Hg. Bolus dosing of labetolol or continuous infusion of nicardipine has been used to achieve target blood pressure. Adjustments in blood pressure parameters may be necessary to achieve clinical stability.

**Antithrombotic regimen.** Postprocedure antithrombotic regimen will likely follow a similar pathway to that in general AIS management. Antithrombotics are usually avoided in the first 24 hours following IV and IA administration of a thrombolytic agent. Certain procedures may present exceptions, such as patients receiving stent implantation, in which the respective preferred regimen will need to be implemented. This may include loading doses of 325 to 650 mg of aspirin (orally or rectally) and 300 to 600 mg of clopidogrel with subsequent dual antiplatelet therapy with daily aspirin (325 mg) and clopidogrel (75 mg) for 4 to 12 weeks, followed by indefinite single-antiplatelet therapy with aspirin 325 mg daily or tailored to the underlying etiology. A potential hazard of dual antiplatelet therapy for acute stent im-

**Glycemia management.** Hyperglycemia may be associated with an increased risk of hemorrhagic transformation of the cerebral infarction. An appropriate glycemic-control regimen will likely be modeled after existing management strategies developed for AIS.

**Statin therapy.** Comprehensive management strategies for patients with AIS who undergo ERT will likely also adopt statin therapy regimens modeled after those developed for AIS patients in general.

**CLINICAL OUTCOME MEASUREMENTS** Monitoring clinical outcomes following ERT is important for quality metrics. Thresholds and benchmarks for acceptable stroke severity–weighted sICH and mortality rates need to be established. The proportion of patients completing 90-day clinical follow-up (from those who are eligible) needs to be established. Similarly, consensus on rates of 90-day good functional mRS outcome (score of 0–2) following ERT needs to be established.

**DISCUSSION** This outline can be used as a framework for the development of future practice recommendations and as an interim tool that the practicing neurovascular specialist can use to assess the rapidly evolving management strategies. This evolving field is marked by ongoing intense investigation of various therapies for acute revascularization, which will demand frequent reevaluation and modification of these strategies.

**AUTHOR CONTRIBUTIONS** All authors participated in the design and revision of the manuscript. Dr. Lazzaro: drafting/revising the manuscript, study concept or design, analysis or interpretation of data. Dr. Novakovics: drafting/revising the manuscript, acquisition of data, statistical analysis, study supervision. Dr. Alexandrov: drafting/revising the manuscript, discussion of review content. Dr. Darkhabani: drafting/revising the manuscript, acquisition of data. Dr. Edgell: drafting/revising the manuscript. Dr. English: drafting/revising the manuscript, analysis or interpretation of data. Dr. Frei: drafting/revising the manuscript. Dr. Jamieson: drafting/revising the manuscript. Dr. Janarthanan: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, development of stroke algorithms and figures for acute ischemic stroke endovascular therapy. Dr. N. Janjua: drafting/revising the manuscript. Dr. Katzan: drafting/revising the manuscript. Dr. Khatri: study concept or design. Dr. Kirmani: study concept or design, study supervision. Dr. Lazzaro: drafting/revising the manuscript, analysis or interpretation of data, acquisition of data. Dr. Lazzaro: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, study supervision. Dr. Nguyen: drafting/revising the manuscript. Dr. Saver: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, study supervision. Dr. Xavier: drafting/revising the manuscript. Dr. Yavagal: drafting/revising the manuscript. Dr. Zaidat: drafting/revising the manuscript, study concept or design, contribution of vital reagents/tools/patients, acquisition of data, statistical analysis, study supervision.
DISCLOSURE

Dr. Lazaro reports no disclosures. Dr. Novakovic performs endovascular treatments for acute ischemic strokes (has not used a retrievable stent). Dr. Alexandrov serves as an Associate Editor for Frontiers in Interventional Neurology; has a patent for Therapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue; has received publishing royalties for Cerebrovascular Ultrasound in Stroke Prevention and Treatment (first and second editions); has served as a consultant for Cerevast Therapeutics; spends 60% effort on clinical stroke service at Comprehensive Stroke Center, UAB Hospital, monitoring endovascular procedures and evaluating success of recanalization with imaging; has received research support from Cerevast Therapeutics, Inc.; has received research support from NIH; has received compensation from Cerevast Therapeutics, Inc.; and has received license fee payments from Therapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue. Dr. Darkhabhani reports no disclosures. Dr. Edell serves as an Associate Editor for Frontiers in Interventional Neurology. Dr. English has served on the scientific advisory board of Concentric Medical Inc., Clinical Events Committee; serves on the editorial boards of Neurohospitalist and The Stroke Interventionalist; and serves as Medical Scientific Advisor for Silk Road Medical. Dr. Frei has served as a consultant to Penumbra, Inc. Dr. Jameson has served as a consultant to Bayer and Boehringer-Ingelheim; served on the speakers bureau for Boehringer-Ingelheim and Merck; served on the scientific advisory board for Bayer and on the Adjudication Committee for ARRIVE trial; and serves as an Assistant Editor for Neurology Alert. Dr. Janardhan reports no disclosures. Dr. N. Janjua serves on the scientific advisory board for Lundbeck/DSMB and Neurointerventions; receives research support from NIH/NINDS; and holds stock or stock options or board of directors compensation for Neurointerventions. Dr. R.M. Janjua reports no disclosures. Dr. Karstan has served as consultant to Pfizer and Genentech; served as a speaker for and received compensation from Cardionet; serves on the Real World Advisory Board for Pfizer; has received research funding from Novartis, Inc., Hoffman-La Roche Ltd, and Takeda Pharmaceuticals; and has received research funding from the Ohio Department of Health. Dr. Khattar is on the Executive Committee of the IMS III Trial, is Neurology PI of the Penumbra THERAPY Trial, and has received research support from Genentech, Inc., for survey implementation; served on the editorial boards of Frontiers in Endovascular and Interventional Neurology; has received research support from the NIH/NINDS; and has served as an expert witness for stroke cases over the last 2 years. Dr. Kirmani served on the advisory board for Otsuka Pharmaceuticals; served as an Associate Editor for Frontiers in Clinical Trials in Neurology, received publishing royalties from the Taylor and Francis Group for The Stroke Center Handbook; receives research support from Penumbra, Inc., and Genentech, Inc.; received research support from NIH/NINDS; and has served as expert witness for stroke cases. Dr. Liebeskind served as a consultant for Concentric Medical and CoAxia and receives research support from NIH. Dr. Linfante served as a consultant for Codman Neurovascular and Stryker; holds stock options in Surpass Limited; serves on the Scientific Advisory Board for Codman Neurovascular; serves on the editorial boards for Stroke and Journal of Neurointerventional Surgery; and serves on the speakers bureau for Codman. Dr. Nguyen serves as Associate Editor of Frontiers in Vascular and Interventional Neurology and Editor of SVIN newsletter The Care; performs intraarterial stroke procedures; and serves as a consultant for Penumbra. Dr. Saver serves on the editorial boards of Stroke, Reviews in Neurologic Disease, Journal of Neuroimaging, and Journal of Stroke and Cerebrovascular Disease; is an employee of the University of California (UC), which holds a patent on retriever devices for stroke; serves on scientific advisory boards, for which the UC Regents receive payments, for CoAxia, Inc., Concentric Medical, Talecris Biotherapeutics, Ferrer, AGA Medical Corporation, BrainGate, PhotoThera, Ev3, and Syngis Bioscience GmbH & Co. KG; is an unpaid site investigator in multicenter clinical trials sponsored by AGA Medical Corporation, Lundbeck, Inc., and Ev3, for which the UC Regents received payments based on clinical trial contracts for the number of subjects enrolled; is an unpaid site investigator in the NIH IRIS, CLEAR, IMS 3, SAMMPRIS, and VERITAS multicenter clinical trials, for which the UC Regents receive payments based on clinical trial contracts for the number of subjects enrolled; receives research support from the NIH and NINDS; receives research support from the AHA; and performs acute stroke care (35%). Dr. Shutter serves on the scientific advisory board for Neuren Pharmaceuticals; receives funding for travel or speaker honoraria from Codman, J&J, and NIH; serves as a consultant for Cincinnati Bengals; receives research support from Department of Defense and NIH (NINDS); receives research support from the Mayfield Education and Research Fund; and holds stock options in UCB Pharma. Dr. Xavier receives research support from Concentric Medical and from Medical University of South Carolina/NIH study. Dr. Yavagal received an honorarium from Penumbra Inc. for consultation and speaking; serves as an Associate Editor for Frontiers in Endovascular Neurology, and serves as a consultant to Penumbra Inc., Codman Neurovascular, Micrus, Inc., Genentech, and Boston Scientific. Dr. Zaidat serves on the scientific advisory board for Teleflex; served on the adjudication committee for Stryker; served speaker honoraria from Stryker; served on the editorial board of Frontiers in Neurology (Endovascular & Interventional Neurology Section); serves as Editor of The Journal of Neurointerventional Surgery, and serves as Associate Editor and is a member of the Editorial Board of Journal of Stroke & Cerebrovascular Diseases; served as a consultant for Stryker Neurovascular, Codman Neurovascular, and Microvention, Inc; and has received research support from Society of Vascular & Interventional Neurology (SVIN) for this educational activity. Go to Neurology.org for full disclosures.

Received December 10, 2011. Accepted in final form February 23, 2012.

REFERENCES


41. Mazighi M, Serfaty JM, Labreuche J, et al. Comparison of intravenous alteplase with a combined intra-
42. Flaherty ML, Woo D, Kissela B, et al. Combined IV and endovascular approach in patients with stroke and con-
43. Rubiera M, Riho M, Pagola J, et al. Bridging intravenous-intra-arterial rescue strategy increases recanalization and the likelihood of a good outcome in nonresponder intravenous tissue plasminogen activator-treated patients: a case-
44. Eckert B, Koch C, Thomalla G, et al. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and ad-
50. Wolfe T, Suarez JL, Tarr RW, et al. Comparison of combined venous and arterial thrombolysis with primary arte-
51. Suarez JL, Sunshine JL, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracra-
Developing practice recommendations for endovascular revascularization for acute ischemic stroke
Marc A. Lazzaro, Roberta L. Novakovic, Andrei V. Alexandrov, et al.
Neurology 2012;79;S243-S255
DOI 10.1212/WNL.0b013e31826959fc

This information is current as of September 24, 2012

Updated Information & Services
including high resolution figures, can be found at:
http://www.neurology.org/content/79/13_Supplement_1/S243.full.html

References
This article cites 60 articles, 41 of which you can access for free at:
http://www.neurology.org/content/79/13_Supplement_1/S243.full.html
##ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://www.neurology.org/content/79/13_Supplement_1/S243.full.html
##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Cerebrovascular disease/Stroke
http://www.neurology.org//cgi/collection/all_cerebrovascular_disease_stroke

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://www.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://www.neurology.org/misc/addir.xhtml#reprintsus